ANTX Company Profile and Key Details

ANTX has shown mixed momentum, gaining 3.51% over the past week and -0.84% over the past quarter, though year-to-date performance is up 3.51%. Short-term trend indicators are bullishly aligned (SMA20 -1.3%, SMA50 -6.15%, SMA200 -7.56%). The stock’s 14-day RSI is 45.06 (neutral), while the ATR of 0.06 points to moderate volatility. The stock remains hovering near 52-week lows, trading -31.61% below its high and over 6.0% above its low. Average 10-day trading volume of 154.35 thousand shares is below the 3-month average of 294.05 thousand, indicating normal recent market interest.

AN2 Therapeutics, Inc. generated EPS of -$1.13 over the past year. Five-year average earnings growth is -41.25%. Wall Street analysts project EPS growth of 22.52% annually over the next five years. The latest quarter delivered EPS of -$0.29. The next quarter is forecast at -$0.24. Next year's EPS is expected at $1.25. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $9.00. The high target offers 82.56% upside. The low target suggests 82.56% downside. The mean target is $9.00. This offers 82.56% upside. AN2 Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 11, 2026, missed forecasts by 26.09%. The prior quarter beat by 20.83%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in March 25, 2025.

AN2 Therapeutics, Inc. has 36.02 million shares outstanding. The public float is 19.98 million shares, elevated short interest at 8.10% of float. This equals 2.44 million shares. The short ratio is 5.3 days. Institutional investors hold 87.64% of the float. Insiders own 18.99%. Shah Rajeev M. holds 3.77 million shares, Leonard Braden Michael has 3.22 million shares and Adjuvant Global Health Technology Fund DE, L.P. has 2.21 million shares. Over the past six months, insider transactions show net selling. They sold 6.54 thousand shares across 3 transactions.

AN2 Therapeutics, Inc. last paid a dividend of 2.62 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.66. This means the shares are trading above this model’s fair value.

AN2 Therapeutics, Inc. (NASDAQ:ANTX) closed at $4.70 USD, losing -$0.23 (-4.67%) from the previous close of $4.93. The stock is currently mid-range between its 52-week high and low $1.00 and $6.91. With a market capitalization of about $169.28 million, AN2 Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.99). Key stats such as the average daily volume over the past year has been around 290.02 thousand shares, volume is running light vs its 52-week average. Headquartered in Menlo Park, CA, AN2 Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Eric E. Easom, the company employs approximately 21 people and listed since March 25, 2022. AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions.

AN2 Therapeutics, Inc. trades at a P/E ratio of -4.3, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.97 suggesting the stock is closer to book value. The P/FCF stands at -5.44, also above market averages.

Our AI price prediction model suggests that AN2 Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected rise of 38.34%, reaching $6.82 by October 23, 2026, with a range of $6.72 to $6.93. 1-Year Outlook: Projected gain of 258.82%, with price at $17.69 by July 27, 2027, within a range of $14.63 to $24.70.

AN2 Therapeutics, Inc. (NASDAQ:ANTX) shares are flat 3.51% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows AN2 Therapeutics, Inc. trading at a premium to the broader market with a P/E of -4.3. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.50, suggesting 173.83% upside.